Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

3.080 UNCHANGED
Official Closing Price Updated: 7:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 Next >
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Alto Neuroscience, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ANRO INVESTOR ALERT: Bronstein, Gewirtz &amp; Grossman LLC Announces That Alto Neuroscience, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi &amp; Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO
From Pomerantz LLP
Via GlobeNewswire
ALTO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of the Alto Neuroscience, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207. 
Via Benzinga
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 
Via Stocktwits
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
Via ACCESSWIRE
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
Via ACCESSWIRE
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
Via ACCESSWIRE
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.